Page 5 - Biocon

Alkem Labs, Ipca, Divi's: Three reasons why pharma stocks are falling today

Stocks such as Natco, Dr. Reddy's, Cipla, Mankind, Torrent, Sun Pharma, Abbott, and Glenmark slipped in the range of 1-2 per cent

Biocon Biologics investors are more confident after revenue growth: Mittal

There is market share gain compared to last year. Any biosimilar might be able to take on a four-five or six player market, said Siddharth Mittal, CEO and MD, Biocon

Biocon Biologics plans IPO for biosimilars business by Mar 2026: CEO

The company, which has been pushing its IPO plans for the past year, has been waiting to complete the integration of its acquired biosimilars firm Viatris and refinance debt before it goes public

Here's why Biocon share price gained 4% despite fall in profits in Q3

Biocon share price gained 3.82 per cent at Rs 370.80 a piece on the BSE in Friday's intraday trade

Biocon Q3 results: Net profit at Rs 25 cr, revenue at Rs 3,821 crore

It also reported a profit before tax (PBT) of Rs 155.9 crore, down 80.8 per cent in Q3FY25

Chandan Taparia of MOFSL recommends buying these stocks on January 21

Bajaj Finserv stock has broken out of a flag and pole pattern on the daily chart with a large bodied bullish candle suggesting strength. The RSI indicator is rising which confirms the upward momentum

Biocon urges govt to exempt cancer, rare-disease drugs from tax in Budget

To make cancer care more affordable in price-sensitive India, Mazumdar-Shaw said, the government must also cut import duties for high-tech instruments

CCI fines Goldman Sachs manager Rs 40 lakh over Biocon deal failure

The Competition Commission has imposed a penalty of Rs 40 lakh on the investment manager of Goldman Sachs AIF for failing to notify the regulator about the more than four-year-old deal that gives the option to buy up to 3.81 per cent stake in Biocon Biologics. The penalty was levied on Goldman Sachs (India) Alternative Investment Management Pvt Ltd (GS AIMPL), the investment manager of Goldman Sachs AIF, for a contravention of Section 6(2) of the Competition Act, which mandates prior approval for certain combinations. Under the deal, Goldman Sachs AIF Scheme-1 (GS AIF) had acquired optionally convertible debentures (OCDs) issued by Biocon Biologics. The regulator has penalised GS AIMPL for failing to notify the transaction to it and rejected the argument that the deal was done in the ordinary course of business. "Any transaction which is made with the intent of remaining invested for a relatively longer period and involves the acquisition of any additional rights (compared to the .

Ajit Mishra of Religare Broking picks Biocon, Marico as stocks to buy today

Stocks to Buy Today: Ajit Mishra of Religare Broking suggests buying Biocon shares and Marico shares. He also suggests shorting Asian Paints shares

Chandan Taparia of MOFSL recommends buying these 3 stocks on January 15

Stocks to buy today, Jan 15: Bajaj Finance share price is on the verge of a breakout from a flag and pole pattern on the daily chart with higher-than-average buying volumes

Biocon extends rally, up 6% in 2 days on HSBC, Motilal Oswal 'Buy' upgrade

Notably, Biocon share price has surged about 6 per cent in the last two sessions

Stocks to Watch, Jan 8, 2025: Tata Steel, Sobha, M&M, REC, SBI, RVNL, CESC

Stocks to Watch, Jan 8, 2025: From Tata Steel to Dr. Reddy's Labs, here is a list of stocks that will remain in focus today

Biocon Biologics marks one year as global biosimilars enterprise

It is targeting a $100 m inventory improvement by March

Biocon share rises 4% as arm gets Japan's PMDA approval for Psoriasis drug

The rise in Biocon stock was also fuelled after Jefferies upgraded the stock to 'Buy', and raised the target to Rs 400

Stocks to Watch, Jan 3, 2025: TaMo, M&M, Airtel, Avenue Supermarts, IOC

Stocks to Watch, Jan 3, 2025: From Avenue Supermarts to Tata Motors, here are few stocks that will be on investors' radar today

Religare Broking's Ajit Mishra says buy these pharma, QSR and auto stocks

Nifty Today, Stocks to Buy Today: The Nifty50 index has now entered its second week of consolidation, and current indicators suggest that this trend is likely to persist

Kiran Mazumdar gets 'Jamsetji Tata Award' for biosciences movement in India

Biocon Group Chairperson Kiran Mazumdar-Shaw was conferred the prestigious Jamsetji Tata Award by the Indian Society for Quality (ISQ) on Saturday for pioneering the biosciences movement in India. "This award holds a very special meaning to me as it is named after one of India's greatest visionaries - a man whose legacy of excellence, innovation, and nation-building continues to inspire us all. Jamsetji Tata's commitment to quality and his belief in the transformative power of industry to serve society resonate deeply with my own journey," said Mazumdar-Shaw. The Jamsetji Tata Award, instituted in 2004 by ISQ recognises business leaders who have made significant contributions to Indian society. The Award was announced at the ISQ Annual Conference 2024, held in Bengaluru. Mazumdar-Shaw received the award from Janak Kumar Mehta, President of ISQ and Chairman and Managing Director, TQM International. "This Lifetime achievement award is being presented to Kiran Mazumdar-Shaw for being

Biocon share falls 4% after USFDA issues VAI tag for Bengaluru's API unit

Biocon's Bengaluru API facility was inspected between September 23 to September 27, 2024

Biocon rises 3% after its arm gets US FDA nod for psoriasis drug YESINTEK

Biocon Biologics Ltd had previously notified on February 29, 2024, that the company had entered into a settlement and licensing agreement with Janssen

USFDA approves Biocon Biologics' biosimilar for Crohn's disease, psoriasis

YESINTEK, a monoclonal antibody, is approved for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis